Latest news with #Eyenovia
Time of India
13 hours ago
- Business
- Time of India
Cryptocurrency Live News & Updates : Eyenovia Stock Soars Over 65% After Financing News
24 Jun 2025 | 11:55:11 PM IST Eyenovia's shares jumped by over 65.2%, boosting its market cap to $26 million, following the announcement of a $50 million PIPE financing initiative for its HYPE strategic reserve plan. Eyenovia has seen a remarkable surge in its stock price, increasing by over 65% after announcing a $50 million PIPE financing initiative aimed at launching its HYPE strategic reserve plan. Meanwhile, Belgravia Hartford Capital has initiated a Bitcoin-focused private placement financing of CAD 10 million, fully backed by Bitcoin reserves, indicating a growing trend of companies leveraging cryptocurrency for funding. Synaptogenix is also entering the crypto space with its acquisition of TAO, part of a broader strategy centered on artificial intelligence and machine learning. In the cryptocurrency market, APT has experienced a significant 17.75% increase, briefly surpassing the $4.8 mark. Conversely, Circle's stock has dropped 15% following a warning from the Bank for International Settlements about the risks associated with stablecoins, despite still being over 600% higher than its IPO price. This mix of soaring stocks and cautionary reports highlights the dynamic and often volatile nature of the cryptocurrency landscape. Show more
Yahoo
7 days ago
- Business
- Yahoo
Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings
NEW YORK, June 18, 2025 /PRNewswire/ -- Chardan, a leading global investment banking and advisory firm, today announced an expansion into the digital asset sector, advising on and structuring a series of transactions that bridge traditional capital markets with the rapidly evolving world of blockchain and cryptocurrency. As part of its strategic push into crypto finance, Chardan has recently served as a strategic advisor and placement agent in the following notable transactions: Eyenovia's $50 Million PIPE to Acquire HYPE Tokens Chardan acted as sole placement agent in Eyenovia Inc.'s (NASDAQ: EYEN) $50 million PIPE financing. The proceeds are being used to acquire over 1 million HYPE tokens, the native asset of the Hyperliquid blockchain, making Eyenovia the first U.S.-listed company to hold HYPE in its treasury. This transaction positions Eyenovia as a top validator on the Hyperliquid network and includes a strategic staking initiative in partnership with Anchorage Digital. The financing involved the issuance of non-voting convertible preferred stock and warrants, potentially raising up to $150 million in total proceeds. Lion Group's $600 Million Facility to Launch Hyperliquid StrategyChardan acted as sole placement agent in Lion Group Holding's (NASDAQ: LGHL) $600 million facility. The facility supports the strategic accumulation of HYPE as a reserve asset, alongside Solana (SOL) and Sui (SUI). This represents LGHL's relaunch of crypto operations and its pivot toward decentralized finance infrastructure. VivoPower's $121 Million PIPE to Launch XRP Treasury StrategyChardan acted as placement agent for the $121 million private placement for VivoPower International PLC (NASDAQ: VVPR). VivoPower is believed to be the first public company to implement an XRP-focused digital asset treasury strategy. Proceeds will be used to acquire XRP, build out a decentralized finance team, and contribute to the XRPL ecosystem. Classover's $500 Million Convertible Notes for Solana Treasury Strategy Chardan served as financial advisor to Classover Holdings, Inc. (NASDAQ: KIDZ) in its $11 million initial tranche which is the first issuance under the $500 million senior secured convertible note financing. Under the terms of the financing agreement, approximately 80% of the net proceeds from the initial tranche will be allocated toward the purchase of Solana (SOL) tokens, subject to certain terms and limitations. Classover has already acquired over 6,400 SOL tokens and is exploring additional opportunities in staking and locked token acquisitions, reinforcing its commitment to blockchain-integrated financial strategy. Chardan's Vision for the Future of Finance "These transactions underscore our commitment to leading the convergence of traditional finance and digital assets," said Jonas Grossman, President and Managing Partner at Chardan. "We are proud to support visionary companies like Eyenovia, VivoPower, Classover, and Lion Group Holding as they redefine capital allocation and treasury management in the Web3 era." Chardan continues to expand its digital asset advisory capabilities, offering bespoke capital markets solutions, tokenomics structuring, and blockchain integration strategies for forward-thinking clients. About Chardan:Chardan is an independent global investment bank specializing in healthcare, digital assets, technology, SPACs, and emerging growth companies. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access, and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, and NASDAQ. Chardan Media Contact: Emily Levine Chief Commercial Officer elevine@ (475) 400-6071 View original content to download multimedia: SOURCE Chardan Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
7 days ago
- Business
- Globe and Mail
Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group
LAGUNA HILLS, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) ('Eyenovia' or the 'Company'), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced several key developments in support of its digital asset capital strategy. Avenue Capital Group, now the Company's largest common stockholder, has agreed to amend Eyenovia's senior secured debt to further support the Company as it builds its HYPE treasury and reserve of the HYPE token. Pursuant to the terms of the amendment, the maturity date of the debt has been extended from November 1, 2025 to July 1, 2028 and its interest rate reduced from 12% to 8%. One half of the interest will be paid monthly in cash with the other half accrued and paid upon maturity. The Company will make interest-only payments during the initial 18 months of the extended term with equal principal and interest payments for the remaining 18 months. Michael Rowe, Chief Executive Officer of Eyenovia, stated, 'We are very grateful to Avenue Capital Group for their significant commitment and support of our innovative treasury strategy. We are pleased that they are positioned as a long-term partner, and we look forward to generating the sustained value creation that we anticipate from this initiative as well as the continued development and potential commercialization of our novel Optejet dispensing platform for the benefit of all shareholders.' Strategic Advisor Appointed for HYPE Treasury Strategy To support the Company's growing presence in the digital asset space, Eyenovia is also pleased to announce the appointment of Max Fiege as Strategic Advisor to support the HYPE Treasury strategy. He will support stakeholder education, ecosystem advocacy, treasury architecture, and risk oversight. Mr. Fiege currently serves as Principal at Merenti Capital GmbH, deploying proprietary capital across liquid and early-stage digital asset opportunities. With a background in blockchain growth and a track record of investing in innovative crypto projects, Mr. Fiege is well recognized for his expertise in navigating and shaping the digital finance landscape. 'It is a privilege to advise Eyenovia on the productive deployment of its HYPE treasury and I look forward to delegating Merenti Capital's own HYPE balance sheet to the Company's validator. Together, we will push the HYPE ecosystem forward,' said Mr. Fiege, Principal at Merenti Capital. 'Arguably no blockchain network has matched Hyperliquid's achievement: friction-free, transparent trading secured entirely on-chain. It is rare that a native token's incentives truly track the network's success. I believe HYPE is the best positioned digital asset for the future and that Eyenovia will effectively capture that value for shareholders.' About the HYPE Token HYPE is the native token of the Hyperliquid layer one blockchain (L1). HYPE is staked by, or delegated to, validators participating in the network's custom consensus algorithm, HyperBFT, which is optimized for order book logic and allows users to trade spot and futures markets in a non-custodial, on-chain fashion. Staked HYPE unlocks further utility in the form of trading fee discounts, with referral bonuses and builder-deployed markets (HIP-3) to be introduced in the future. Circulating HYPE is autonomously bought back and sequestered with trading fees accrued on the network's enshrined markets. As of June 2025, HYPE has become the 12th-largest cryptocurrency by market capitalization. About Eyenovia, Inc. Eyenovia, Inc. is a pioneering digital ophthalmic technology company and the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE. With this dual focus, Eyenovia continues to revolutionize topical eye treatment while providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility. Eyenovia is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products, spanning multiple billion-dollar markets. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. For more information, please visit Forward Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our new cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Business Insider
20-05-2025
- Business
- Business Insider
Eyenovia provides update on potential merger and Optejet development
Eyenovia (EYEN) provided updates on its potential merger with Betaliq and the ongoing development of its novel Optejet user filled device or UFD. Negotiations continue towards a binding merger agreement with Betaliq, a clinical-stage private pharmaceutical company focused on glaucoma with access to Eyesol, a non-aqueous technology that may address many of the needs of these patients. The companies have agreed to extend the binding exclusivity period set forth in the Letter of Intent until June 7 to allow more time to complete and execute the anticipated merger agreement. Progress in the development of the Optejet UFD continues and remains on track to file for U.S. regulatory approval in September of this year. An approval would provide for potential multiple commercial opportunities either directly with consumers or through eye care practitioner offices as well as potential and existing license partners, including Arctic Vision in China and Korea. A broad restructuring of the company was implemented, reducing overall cash burn by approximately 70% versus one year ago and entering into a debt restructuring agreement earlier this year which defers certain repayment obligations until October 2025.
Yahoo
19-05-2025
- Business
- Yahoo
Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results
Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the proprietary Optejet® topical ophthalmic medication dispensing platform, today provided updates on its potential merger with Betaliq and the ongoing development of its novel Optejet user filled device (UFD), and reported financial results for the first quarter ended March 31, 2025. Potential Merger with Betaliq Negotiations continue towards a binding merger agreement with Betaliq, a clinical-stage private pharmaceutical company focused on glaucoma with access to Eyesol®, a non-aqueous technology that may address many of the needs of these patients. We have agreed to extend the binding exclusivity period set forth in the Letter of Intent until June 7, 2025, to allow more time to complete and execute the anticipated merger agreement. Development of the Optejet UFD Progress in the development of the Optejet user-filled device (UFD) continues and remains on track to file for U.S. regulatory approval in September of this year. An approval would provide for potential multiple commercial opportunities either directly with consumers or through eye care practitioner offices as well as potential and existing license partners, including Arctic Vision in China and Korea. First Quarter 2025 Financials A broad restructuring of the company was implemented, reducing overall cash burn by approximately 70% versus one year ago and entering into a debt restructuring agreement earlier this year which defers certain repayment obligations until October 2025. Michael Rowe, Chief Executive Officer, commented, 'We remain focused on seeking to maximize shareholder value by working to complete a definitive merger agreement with Betaliq that, if and when completed, will create a new eyecare company with immediate revenue through the sale of our existing FDA-approved products and significant pipeline opportunities that we believe leverage complementary FDA-approved technologies, including our Optejet® platform.' 'At the same time, our engineering team continues to advance the development of our user-filled Optejet, which, if approved, would have the potential to address many of the shortcomings of traditional eyedrops, most notably ease of use and reduced waste. We look forward to submitting an application for device regulatory approval in September of this year and introducing this novel device that can deliver an enhanced experience across a broad range of uses.' 'In addition to these strategic initiatives, we took important measures over the past several months to reduce expenses, strengthen our balance sheet, and extend our cash runway. Perhaps the most notable of these is our entry into a debt restructuring agreement with Avenue Capital, which continues to be very supportive as we work toward finalizing a merger agreement with Betaliq. We look forward to the completion of this potential merger and believe we have set the stage for multiple value inflection points this year,' Mr. Rowe concluded. First Quarter 2025 Financial Review For the first quarter of 2025, net loss was $3.5 million, or $1.59 per share. This compares to a net loss of $10.9 million, or $18.75 per share, for the first quarter of 2024. Research and development expenses totaled $0.7 million for the first quarter of 2025, compared to $4.4 million for the first quarter of 2024, a decrease of 85%. For the first quarter of 2025, general and administrative expenses were $2.4 million, compared to $3.6 million for the first quarter of 2024, a decrease of 35%. Total operating expenses for the first quarter of 2025 were $3.0 million, compared to $10.1 million for the first quarter of 2024. This represents a decrease of 70%. As of March 31, 2025, the Company's unrestricted cash and cash equivalents were $3.9 million, as compared to $2.1 million in unrestricted and restricted cash as of December 31, 2024. About Eyenovia, Inc. Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The Company's current commercial portfolio includes clobetasol propionate ophthalmic suspension, 0.05%, for post-surgical pain and inflammation, and Mydcombi® for mydriasis. For more information, please visit Forward Looking Statements Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to the potential transaction with Betaliq, our future activities or other future events or conditions, including those relating to the completion of due diligence on and a definitive transaction agreement with Betaliq, the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: the risk that the proposed transaction with Betaliq does not proceed; risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements. Eyenovia Contact:Eyenovia, Lowenlowe@ Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@ 751-4363EYENOVIA, INC. Condensed Balance Sheets March 31, December 31, 2025 2024 (unaudited) Assets Current Assets Cash and cash equivalents $ 3,934,966 $ 2,121,463 License fee and expense reimbursements receivable 25,787 24,827 Security deposits, current 14,968 14,968 Prepaid expenses and other current assets 1,183,262 605,941 Total Current Assets 5,158,983 2,767,199 Security deposits, non-current 182,200 182,200 Operating lease right-of-use asset 642,770 718,360 Total Assets $ 5,983,953 $ 3,667,759 Liabilities and Stockholders' Deficiency Current Liabilities: Accounts payable $ 1,199,961 $ 2,199,768 Accrued compensation 109,934 144,161 Accrued expenses and other current liabilities 3,241,554 3,178,513 Operating lease liabilities - current portion 542,561 575,163 Notes payable - current portion, net of debt discount of $56,954 and $527,870 as of March 31, 2025 and December 31, 2024, respectively 729,999 5,212,532 Convertible notes payable - current portion, net of debt discount of $723,725 and $263,930 as of March 31, 2025 and December 31, 2024, respectively 9,276,275 4,736,070 Total Current Liabilities 15,100,284 16,046,207 Operating lease liabilities - non-current portion 597,670 717,504 Total Liabilities 15,697,954 16,763,711 Stockholders' Deficiency: Preferred stock, $0.0001 par value, 6,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2025 and December 31, 2024 Common stock, $0.0001 par value, 300,000,000 shares authorized; 2,830,546 and 1,506,369 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively 283 151 Additional paid-in capital 189,079,241 182,213,889 Accumulated deficit (198,793,525 ) (195,309,992 ) Total Stockholders' Deficiency (9,714,001 ) (13,095,952 ) Total Liabilities and Stockholders' Deficiency $ 5,983,953 $ 3,667,759 EYENOVIA, INC. Condensed Statements of Operations (unaudited) For the Three Months Ended March 31, 2025 2024 Operating Income Revenue $ 14,720 $ 4,993 Cost of revenue (48 ) (203,027 ) Gross Profit 14,672 (198,034 ) Operating Expenses: Research and development 673,043 4,431,601 Selling, general and administrative 2,372,322 3,637,189 Reacquisition of license rights - 2,000,000 Total Operating Expenses 3,045,365 10,068,790 Loss From Operations (3,030,693 ) (10,266,824 ) Other Income (Expense): Other (expense) income, net 3,687 (97,558 ) Gain on debt extinguishment 89,623 - Interest expense (581,499 ) (678,658 ) Interest income 35,349 120,939 Total Other Expense (452,840 ) (655,277 ) Net Loss $ (3,483,533 ) $ (10,922,101 ) Net Loss Per Share - Basic and Diluted $ (1.59 ) $ (18.75 ) Shares Outstanding - Basic and Diluted 2,188,938 582,584 Sign in to access your portfolio
